… Different vaccine candidates have been investigated but … vaccines. Here, we investigated
the immunogenicity of naked DNA vaccines expressing different fragments of MERS-CoV S …

… , given that MERS coronavirus appears to … MERS coronavirus, 3, 4 and WHO has developed
a target product profile for both preventive and reactive use of MERS coronavirus vaccines. …

… vaccine has not been developed for it. To develop a vaccine against multiple strains of
MERS-CoV, we targeted spike glycoprotein (S) using prime-boost vaccination with DNA and …

… MERS-CoV infection, describes MERS vaccine criteria, and presents available small animal
models to evaluate the efficacy of MERS vaccines. … such DNA vaccines encode MERS-CoV …

… to develop DNA-based vaccines against MERS-CoV infection, suitable measures such as
priming-boost strategy or combination of DNA vaccines with other vaccination types should be …

… baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome
coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-…

… the need for effective approaches to CoV vaccine development. Efforts focused solely on …
DNA and S1 subunit protein elicit robust serum-neutralizing activity against several MERS-CoV …

… Here, we illustrate the importance of the MERS-CoV S protein as a key vaccine target and
… MERS-CoV DNA vaccines utilize different vectors to encode the full-length MERS-CoV S …

… , eg a full-length S-based simian adenovirus vector vaccine (ChAdOx1) and a DNA vaccine
(GLS-5300), are scheduled for clinical trials (Phase I) to test their safety and immunogenicity […

… the GLS-5300 MERS coronavirus DNA vaccine was tolerable and immunogenic in humans.
The vaccine induced both antibody-based and cellular MERS coronavirus-specific immune …